Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Translate Bio, Sanofi Pasteur close vaccine deal
September 2018
SHARING OPTIONS:

LEXINGTON, Mass.—Translate Bio and Sanofi Pasteur have closed their previously announced research collaboration and licensing agreement, following notice of early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The agreement, announced on June 11, is slated to run multiple years and covers the development of mRNA vaccines for up to five undisclosed infectious disease pathogens. In keeping with the terms of the agreement, Sanofi Pasteur will make an upfront payment to Translate Bio of $45 million. All told, Translate Bio could receive up to $805 million in payments, which includes the upfront payment as well as development, regulatory and sales-related milestones and option exercise fees if Sanofi Pasteur exercises its option for additional pathogens. Sanofi Pasteur will cover all costs during the three-year research term, and will have exclusive worldwide commercialization rights.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.